glp-1 compounding news november 2025 Patients struggle as compounded access rapidly shrinks Fight over GLP-1 compounding plays

The peptides frequently being referenced in reclassification conversations include: AOD-9604 BPC-157 Emideltide (DSIP Delta Sleep-Inducing Peptide) Epitalon (Epithalamin) GHK-Cu (Copper Peptide) Kisspeptin-10 KPV MOTS-C Semax Selank TB-500 (Thymosin Beta-4 Fragment) Thymosin Alpha-1 Despite public discussion, these peptides remain categorized as Category 2 under current FDA policy and are not eligible for patient-specific 503A compounding

Each company filed continuation patents, pursued new indications, and built defensive walls around their core molecules

They can boost collagen and elastin, which can help anchor the hair more securely and reduce shedding

Bile acids attenuate PKM2 pathway activation in proinflammatory microglia

a 130-week, open-label, extension period